Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 3, 2009, Pages 699-708

  Tsien, Christina ^a   Moughan, Jennifer ^b   Michalski, Jeff M ^c   Gilbert, Mark R ^d   Purdy, James ^e   Simpson, Joseph ^c   Kresel, John J ^f   Curran, Walter J ^g   Diaz, Aidnag ^h   Mehta, Minesh P ⁱ  

^a UNIVERSITY OF MICHIGAN   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BARROW NEUROLOGICAL INSTITUTE   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

3D CRT; Dose escalation; Glioblastoma

Indexed keywords

CHEMOTHERAPY; FLUORESCENT SCREENS; ONCOLOGY; RADIOTHERAPY; TELEVISION PICTURE TUBES; THREE DIMENSIONAL; TUMORS;

3D-CRT; CARMUSTINE; CENTRAL NERVOUS SYSTEMS; CONCURRENT CHEMOTHERAPIES; DOSE ESCALATION; DOSE LEVELS; DOSE-LIMITING TOXICITIES; GLIOBLASTOMA; GROSS TUMOR VOLUMES; MEDIAN SURVIVALS; PHASE I; PLANNING TARGET VOLUMES; PRE TREATMENTS; RADIATION THERAPY ONCOLOGY GROUPS; THREE-DIMENSIONAL CONFORMAL RADIOTHERAPIES;

TOXICITY;

CARMUSTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SURVIVAL; TOXICITY; TREATMENT PLANNING; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; CARMUSTINE; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NECROSIS; PROSPECTIVE STUDIES; QUALITY CONTROL; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; REOPERATION; STEROIDS; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 59649097862     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.034     Document Type: Article

References (24)

1. Mahley M.S., Mettlin C., Natarajan N., et al. National survey of patterns of care for brain-tumor patients. J Neurosurg 71 (1989) 826-836
2. Wallner K.E., Galicich J.H., Krol G., et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncology Biol Phys 16 (1989) 1405-1409
3. Chan J., Lee S., Fraass B., et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20 (2002) 1635-1642
4. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
5. Arbuck SG, Ivy SP, Setser A, et al. The revised common toxicity criteria: Version 2.0. Available at: http://ctep.info.nih.gov. Accessed September 1, 2007.
6. Cox J.D., Stetz J., Pajak T.F., et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
7. Thornton Jr. A.F., Hegarty T.J., TenHaken R.K., et al. Three dimensional treatment planning of astrocytomas: A dosimetry study of cerebral irradiation. Int J Radiat Oncol Biol Phys 20 (1991) 1309-1315
8. Fitzek M.M., Thornton A.F., Rabinov J.D., et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: Results of a phase II prospective trial. J Neurosurg 92 (1999) 251-260
9. Tanaka M., Ino Y., Nakagawa K., et al. High-dose conformal radiotherapy for supratentorial malignant glioma: A historical comparison. Lancet Oncol 6 (2005) 953-960
10. Sheline G.E., Wara W.M., and Smith V. Therapeutic irradiation in brain injury. Int J Radiat Oncol Biol Phys 6 (1980) 1215-1228
11. Marks L., and Spencer D. The influence of volume on the tolerance of the brain to radiosurgery. J Neurosurg 75 (1991) 177-180
12. Kong F.M., Hayman J.A., Griffith K.A., et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65 (2006) 1075-1086
13. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53 (2002) 810-821
14. Shaw E., Scott C., Souhami L., et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial report of Radiation Therapy Oncology Group protocol (90-05). Int J Radiat Oncol Biol Phys 34 (1996) 647-654
15. Coughlin C., Scott C., Langer C., et al. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48 (2000) 1351-1358
16. Werner-Wasik M., Scott C.B., Nelson D.F., et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group study 83-02. Cancer 77 (1996) 1535-1543
17. Lustig R.A., Seiferheld W., Berkey B., et al. Imaging response in malignant glioma, RTOG 90-06. Am J Clin Oncol 30 (2007) 32-37
18. Van R., Heimans J., van den Berg J., et al. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int J Radiat Oncol Biol Phys 47 (2000) 779-784
19. Chakravarti A., Erkkinnen M.G., Nestler U., et al. Temozolomide-mediated radiation enhancement in glioblastoma multiforme: A report on underlying mechanisms. Clin Cancer Res 12 (2007) 4738-4746
20. Perry A., and Schmidt R.E. Cancer therapy-associated CNS neuropathology: An update and review of the literature. Acta Neuropathol 111 (2006) 197-212
21. MacDonald S.M., Ahmad S., Kachris S., et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: A dosimetric comparison. J Appl Clin Med Phys 8 (2007) 47-60
22. Nelson S.J., Graves E., Pirzkall A., et al. In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI. J Magn Reson Imaging 16 (2002) 464-476
23. Grosu A.L., Weber W.A., Franz M., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 511-519
24. Chen W., Delaloye S., Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25 (2007) 4714-4721